MedTrace Logo

A Phase 1/2 Trial of ADI-212 in mCRPC

NCT07793435 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-08-28

No results posted yet for this study

Summary

This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)

Conditions

  • PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG

ADI-212

Allogeneic cell therapy

DRUG

Fludarabine

Chemotherapy for Lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for Lymphodepletion

Sponsors & Collaborators

  • Adicet Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-10-31
Completion
2029-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07793435 on ClinicalTrials.gov